early termination of debt/credit facilities (see note (f) for
details); certain other gains or losses that are either isolated or
cannot be expected to occur again with any regularity or
predictability (see note (g) for details); the tax consequences of the
preceding items and other tax events (see note (h) for details); and
results of discontinued operations.
(c) Reported results in 2007 include $49.2 primarily for charges for the
sale of inventories revalued at the date of acquisition. Reported
results in 2006 include $74.8 of charges for the sale of
inventories revalued at the date of acquisition and $2.9 of
accelerated depreciation on manufacturing assets abandoned due to
(d) Reported results in 2007 and 2006 include restructuring and other
costs, net, consisting principally of severance, abandoned facility
and other expenses of real estate consolidation and, in 2007,
loss on sale of business, net of net gains in 2006 on the sale of
product lines and abandoned facilities. Reported results in 2006 also
include $15.2 of charges for in-process research and
development associated with the Fisher merger.
(e) Reported results in 2006 include a charge for the acceleration of
equity-based compensation expense due to a change in control.
(f) Reported results in 2006 include $0.9 of cost associated with the
early termination of debt/credit facilities in interest expense.
(g) Reported results in 2007 included an $8.9 loss from an other than
temporary decline in the fair market value of an available-for-sale
investment and a $4.5 currency transaction gain associated with an
intercompany financing transaction.
(h) Reported provision for income tax
|SOURCE Thermo Fisher Scientific Inc.|
Copyright©2008 PR Newswire.
All rights reserved